ECOFECT


Séminaire externe du CIRI : Dr. Andrew Davidson

Colloque / Séminaire

Share |

le 10 juillet 2014 /

Le Centre International de Recherche en Infectiologie organise une conférence avec le Dr. Andrew Davidson le 10 juillet 2014 avec le soutien d’ECOFECT…

Andrew Davidson de l'équipe de virologie de l’University of Bristol (UK) donnera une conférence le jeudi 10 juillet à 10h00 à l’amphithéâtre SVT à l’ENS-L sur « High throughput quantitative proteomic analysis of dengue virus – host cell interactions ».

Andrew Davidson s’intéresse particulièrement à l’étude de la réplication et de la pathogenèse du virus de la Dengue et du coronavirus SARS avec l’objectif global de développer de nouveaux agents antiviraux et des vaccins.

Pour en savoir plus sur A. Davidson : http://www.bristol.ac.uk/cellmolmed/research/infect-immune/davidson.html

Contact : Marlène Dreux (marlene.dreux@ens-lyon.fr)

Résumé de la conférence :
Dengue virus (DENV) causes the most significant arthropod-borne viral disease of humans, with an estimated 400 million infections annually, worldwide. We are using a combination of high throughput mass spectrometry based proteomic approaches to identify cellular proteins that interact with DENV proteins to either promote or restrict virus replication.
In an initial study, nuclear and cytoplasmic fractions from DENV-2 infected human cells were analyzed. Bioinformatic analysis of the data led to the identification of cellular pathways and protein functional groups altered in response to DENV infection. Alterations in the amounts of representative proteins were confirmed by Western blotting and immunofluorescence assay. Stable inducible over-expression of two proteins (PRAF2 and ERC1), that were almost undetectable after DENV infection was found to inhibit virus infection. High-throughput co-imunoprecipitation analysis using cells over-expressing PRAF2 and ERC1 has been done to indentify DENV proteins interacting with the cellular proteins and changes to the interactome of these proteins during virus infection. In addition, our comparative analysis of different serotypes (DENV-2 and -4) lead to the identification of proteins that are significantly increased in the replicase containing fraction. The effect on DENV replication of depleting these proteins is currently being investigated.